Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03729258
Other study ID # NEU-04.15
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 15, 2019
Est. completion date December 1, 2023

Study information

Verified date January 2023
Source Neutec Ar-Ge San ve Tic A.S
Contact Neutec RDC
Phone 00905051747902
Email iremkaraman@neutecrdc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years and older patients who have acute bacterial rhinosinusitis sign and symptoms (i, ii, iii) according to IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults: i. Onset with persistent symptoms or signs* compatible with acute rhinosinusitis, lasting for = 10 days without any evidence of clinical improvement, ii. Onset with severe symptoms or signs of high fever > 39 and purulent nasal discharge or facial pain lasting for at least 3-4 consecutive days at the beginning of illness, iii. Onset with worsening symptoms or signs characterized by the new onset of fever, headache, or increase in nasal discharge that lasted 5-6 days and were initially improving. (*Major symptoms: Purulent anterior nasal discharge, Purulent or discolored posterior nasal discharge, Nasal congestion or obstruction, Facial congestion or fullness, Facial pain or pressure, d Hyposmia or anosmia. *Minor symptoms: Headache, Ear pain, pressure, or fullness, Halitosis, Dental pain, Cough, Fatigue) 2. Patients who are able to give culture sample from middle meatus (microorganisms to be teste: Streptococcus pneumoniae, Haemophilus influenzae [including beta-lactamase producing strains], Streptococcus pyogenes and Moraxella catarrhalis [including beta-lactamase producing strains]). 3. Patients who are able to use oral drugs, 4. If patient is a women of childbearing age; female patients who applies appropriate birth control, 5. Patients who have ability to communicate with investigators, 6. Patients who commits to adhere to the study protocol, 7. Patients who sign informed consent form. Exclusion Criteria: 1. Patients who have hypersensitivity to beta-lactam antibiotics, penicillin and cefpodoxime, 2. Patients who hypersensitivity to peanut and soy, 3. Patients who have kidney or liver deficiency, 4. Patients who have history of more than 2 bacterial sinusitis episode within last 12 months, 5. Patients who have chronic sinusitis, 6. Patients who have history of head and neck surgery and/or severe sinusitis complication (brain abscess or venous thrombosis), 7. Patients who are hospitalized within 4 weeks prior to the start of study, 8. Patients who have immunodeficiency (i.e; HIV, corticosteroid use, immunosuppressive use), 9. Patients who used antibiotics within 30 days prior to the start of study, 10. Patients who need to use of antibiotics other than investigational drugs for concomitant disease, 11. Patients who used aluminium and magnesium containing anti-acids, probenecid and iron containing drugs within 2 weeks prior to the start of study, 12. Pregnant and lactating female patients.

Study Design


Intervention

Drug:
Infex 400 MR
Infex (cefpodoxime) 400mg once a day (QD) for 10 days
Infex 200 IR
Infex (cefpodoxime) 200mg twice a day (BID) for 10 days

Locations

Country Name City State
Turkey Bakirköy Dr. Sadi Konuk Training and Research Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of formulations on acute sinusitis symptoms Change in acute sinusitis sign and symptoms at the end of treatment compared to baseline.
The outcome will be assessed by Sino-nasal Outcome Tests SNOT-22 and SNOT-16.
* SNOT-16 is recommended symptom questionnarie for acute rhinonusitis but Turkish validation is not existed. Therefore SNOT-22 is also added as a symptom questionnarie since Turkish Validation is available.
10 days
Primary Effect of formulations on quality of life scale Quality of Life: Increase or decrease in quality of life. The outcome will be assessed by Short Form Health Survey (SF-12). 10 days
Primary Rate of microbiological response at the end of treatment Patients will be given sample from middle meatus.
The outcome will be assessed according to microbiologic response:
Eradication: The absence of pathogen(s) at the end of treatment. Persistance: The same concentration of the pathogen(s) in culture after the end of treatment.
Superinfection: Detection of bacterial of fungal pathogens during or after treatment,
10 days
Secondary Evaluation of the safety of investigational products Number of Adverse Events That Are Related to Treatments and Participants with Abnormal Laboratory Values (hemogram, sedimentation, CRP) 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT03584178 - The Long-Term Safety of Budesonide for Patients With Chronic Rhinosinusitis N/A
Completed NCT06016335 - MRI-based Synthetic CT Images of the Head and Neck N/A
Active, not recruiting NCT02278484 - Sinus Balloon Dilation in Pediatric Patients N/A
Withdrawn NCT02071667 - Association of Periostin Levels and Chronic Sinusitis N/A
Completed NCT01420471 - Medicated Punctured-Glove-Finger Spacer Study Phase 4
Completed NCT01118312 - Study of Asthma and Nasal Steroids Phase 4
Completed NCT00645762 - Balloon REmodeling Antrostomy THErapy Study Phase 2
Completed NCT01685229 - Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis
Active, not recruiting NCT03943121 - The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps N/A
Withdrawn NCT02900794 - Gold Laser Vs. Micro-Debriders for Functional Endoscopic Sinus Surgery N/A
Terminated NCT02630472 - Topical Irrigation Therapy for CRS Phase 1/Phase 2
Completed NCT01442740 - 15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients N/A
Completed NCT01001039 - Validation of the Facial and Cephalic Pain Inventory N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00335309 - Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis N/A
Completed NCT00242437 - Hemostatic Matrix in Endoscopic Sinus Surgery Phase 4
Completed NCT00236522 - A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults. Phase 3
Completed NCT01717274 - Hot Saline Irrigation Study N/A
Completed NCT01166945 - Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children N/A
Completed NCT00747747 - Sinuclean's Treatment Of Sinusitis' Symptoms Phase 4